Andrea Visentin

Assistant professor

University of Padua

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Andrea Visentin is an Assistant Professor at the University of Padua in Italy. His research focuses on chronic lymphocytic leukemia (CLL), exploring areas such as the role of protein phosphatase 2A in cancer treatment, immune system interactions in hematological tumors, and the clinical characterization of CLL patients. His recent publications include studies on disease-specific RNA mutations and management strategies for patients with complex karyotypes.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (19)

Laura Hilton

Adjunct Professor

Simon Fraser University

CANADA

Andrea Visentin

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

Interplay Between Protein Phosphatase 2A (PP2A) and SE Translocation (SET) as Macromolecular Target of Anticancer Compounds: A Combined Computational and Experimental Study

Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control Study

Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype

Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemia

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study

Editorial: Immune system interactions in hematological tumor microenvironments: pathways to innovative treatments

Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia

Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy

A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report

Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax‐based regimens

Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

POEMS syndrome associated with IgM lambda paraprotein. A case report and review of the literature

When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario

Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review

Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course

How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature

Focal adhesion kinase activation by calcium‐dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness

Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy

Continuous venetoclax in treatment‐naive <scp><i>TP</i>53</scp> disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Collaborators (19)

Laura Hilton

Federica Frezzato

Angelica Barone

Francesca Romana Mauro

Julio Delgado

Alberto Fresa

Marta COSCIA

Silvia Scaranzin

PAOLO SPORTOLETTI

Moritz Fürstenau

Marika Vezzoli

Giuseppe Maggioni

Francesco Piazza

Candida VITALE

Panagiotis Baliakas

Annalisa Angelini

Roberta Sommaggio

Livio Trentin

Francesco Angotzi

Make your next move.